Comend

Comend is a technology company building infrastructure to support patient-led research groups and rare disease communities. The company aims to empower these groups to organize, accelerate, and broadcast their research efforts to academics, drug developers, and donors. By providing specialized tools, Comend seeks to de-risk rare disease drug development and facilitate the creation of patient-led biotechs. Their product suite includes a crowdsourced search platform for rare disease and disability resources, as well as an AI-powered scientific translator, with further marketplace solutions in development. All tools are co-designed in collaboration with rare disease families.

The company serves as a vital resource for patient groups that often lack the technical infrastructure needed to manage complex research projects, biobanks, and funding initiatives. By bridging the gap between patient engagement and scientific innovation, Comend helps simplify the development of treatments for genetic disorders. The startup is backed by investors including Character VC and Drive Capital, and it maintains a presence in Toronto, Canada, and the United States, working to modernize how patient advocacy groups interact with the broader life science ecosystem.